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ABSTRACT
█    CASE REPORT
A 39-year-old man presented with progressive headache. 
Magnetic resonance imaging (MRI) showed a gadolinium-
enhanced tumor, which was located in the left frontal lobe 
and invaded anterior supratentorial structures towards the 
midline (Figure 1A, B). On August 2006, the patient underwent 
the first operation. The lesion was subtotally removed and the 
histopathological diagnosis was GBM, grade IV grade glioma 
according to the WHO classification system. The status of 
MGMT gene promoter was methylated. The patient underwent 
60 Gy radiotherapy delivered in 30 fractions and concurrent 
and subsequent chemotherapy with temozolomide according 
to standard schedules. The patient was followed-up with 
periodic neuroimaging studies and clinical examinations for 
two years. Six months later, there was evidence of tumor 
recurrence (Figure 2A). After standard adjuvant treatment 
with temozolomide, the tumor growth slowed down until 
March 2008 (Figure 2B). On June 2008, there was again 
█    INTRODUCTION 
Glioblastoma (GBM) is the most malignant primary cere-bral tumor in adults. Despite its aggressive biological nature, invasion of the dura mater and subsequent 
growth into the facial cavities are very rare. Some authors 
reported the spontaneous dura mater and bone involvement 
by GBM and anaplastic oligodendroglioma (11, 14) without 
subsequent extracerebral growth. When the dura mater is 
surgically disrupted, extracerebral growth may be observed 
(5). Spontaneous dural penetration associated with extracere-
bral growth of GBM was previously reported (1,3,6,14). All of 
them, except one (3), were reported before the World Health 
Organisation (WHO) central nervous system (CNS) tumor clas-
sification in 1993. 
We report here a case of histologically proven GBM that was 
treated by repeated operations and adjuvant therapy. The last 
recurrence of this tumor presented with spontaneous dura 
mater penetration and nasal cavity invasion.  
Glioblastoma (GBM) is the most aggressive primary tumor of the central nervous system (CNS) in adults. Its growth has been always 
described as locally invasive. This tumor rarely penetrates dura mater and invades extracranial structures. We present a case of 
GBM, which occurred in a 39-year-old man, with final involvement of the nasal cavity. The patient was operated four times in three 
years, and a personalized adjuvant chemotherapy regimen was administered in a neo-adjuvant fashion. Histopathological features 
of the tumor are described. To our knowledge, there are only 9 cases reported in the literature showing this growth pattern and the 
last case was reported in 1998.       
KEywORDS: Glioblastoma, Recurrence, Surgery, Temozolomide, Long-term survival, Nasal cavity, Dura mater
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evidence of tumor recurrence (Figure 2C). MRI images 
showed a contrast-enhancing lesion on the basal surface 
of left frontal lobe, surrounded with edema on T2-weighted 
images. Therefore, re-operation was performed twenty-five 
months after the first surgical procedure and subtotal tumor 
removal was achieved (Figure 2D). The postoperative course 
was uneventful (Karnofsky Performance Scale score was 
100). Histopathological analysis confirmed the diagnosis 
of recurrent GBM. Eleven weeks after surgery, MRI scans 
revealed a second relapse of the tumor which was larger 
and more lateral than the first relapse (Figure 3A). The tumor 
also involved the corpus callosum. The patient underwent 
personalized adjuvant chemotherapy regimen. A re-challenge 
with temozolomide following a dose-dense schedule was 
performed. A metronomic daily administration of temozolomide, 
50 mg per square meter of body-surface area was used. 
At the 5th month of medical treatment, neuroradiological 
control imaging showed decrease of the lesion size, with the 
disappearance of corpus callosum involvement (Figure 3B). 
On January 2009, the patient underwent re-operation for the 
third time and the tumor was totally removed (Figure 3C). The 
surgical approach was performed through the operculum, and 
anterior dura mater was left intact. Postoperative neurological 
examination was normal. Adjuvant chemotherapy was started 
again and there was a four-month interval between the 
surgery and the third relapse of the tumor. On the 4th month 
after surgery, MRI revealed the third recurrence of GBM which 
invaded the nasal fossa by penetrating the anterior dura 
mater, the basal surface of left frontal lobe, extending down 
to olfactory scrolls, causing lateral drift of the left optic bulb 
(Figure 4A-D). The patient underwent to transnasal biopsy of 
the lesion showing the presence of necrosis and glial fibrillary 
acidic protein (GFAP)-vimentine-Ki67 positive cells (40%). The 
diagnosis was again GBM. Last 2 surgical procedures were 
performed by neurosurgical and maxillo-facial teams. Firstly, 
surgical removal of residual tumor fragments in the frontal 
lobe and dural reconstruction by Tachosil®, Floseal® and 
Surgicel® with titanium plate were performed (Figure 5A-C). 
Secondly, nasal part of the GBM was totally removed with 
the endoscopic technique. In the early postoperative period, 
the patient was in good clinical condition. Two months later, 
the patient died due to septic shock secondary to meningeal 
infection. Histopathological specimens showed massive dural 
infiltration by glioblastoma cells at the site of a primitive tumor 
(Figure 6A), and nasal mucosa infiltration by glioblastoma cells 
forming solid nests. There were cells with pleomorphic nuclei 
and the classic glassy and eosinophilic cytoplasm of astrocytes 
on high magnification (Figure 6B, C). Immunohistochemical 
evaluation revealed the cytokeratin positivity in the epithelial 
cells of the respiratory mucosa and strong positivity for GFAP 
(Figure 6D, E). 
█    DISCUSSION 
GBM, the most common primary brain tumor in adults, is usu-
ally fatal. The standard care for a newly diagnosed GBM is 
surgical resection, followed by adjuvant radiotherapy and che-
motherapy (temozolomide). The prognosis for these gliomas 
is poor. Median survival after the diagnosis is approximately 1 
year (9). With adjuvant treatments, this prognosis can improve. 
Temozolomide is an oral alkylating agent, used in conventional 
schedule at a dose of 150 to 200 mg per square meter of 
body-surface area for 5 days of a 28-day cycle. 75 mg per 
square meter daily for up to seven weeks is useful to deplete 
the DNA-repair enzyme O6-methylguanine-DNA methyltrans-
ferase (MGMT). The MGMT gene is located on chromosome 
10q26 and encodes a DNA-repair protein that removes alkyl 
groups from the O6 position of guanine. Restoration of the 
DNA consumes MGMT protein and the cells must replenish. 
In case of missing MGMT protein, chemotherapy can induce 
DNA-lesioning and trigger cytoxicity and apoptosis. 
MGMT promoter methylation in GBM is associated with 
benefit of temozolomide treatment (4). Through this treatment, 
survival of GBM patients have been increased (15). GBM does 
not usually show leptomeningeal invasion. In fact, dura mater 
is the most important barrier for extracranial extension. There 
are biological differences between the invasive behavior of 
gliomas and non-neuroepithelial tumors. Leptomeningeal 
cells and associated acellular components of dura mater may 
Figure 1: MRI scan of the lesion 
at its first appearance in June 
2006, as it appears on contrast-
enhanced axial (A) and coronal (B) 
T1 sequence.
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Figure 2: Post-contrast axial T1 MRI 
shows first recurrence of the disease 
after surgery and concomitant radio-
chemotherapy (A); MRI contrast-
enhanced T1 axial scan after 15 
cycles of conventional temozolomide, 
administered 5 days of every 28, 200 
mg/m2 body surface (B); MRI enhanced 
axial T1 image, showing tumor relapse 
after twenty-two months from surgery 
(C); MRI post-contrast T1-weighted axial 
image showing the surgical cavity after 
second operation (D).
Figure 3: T1 post-contrast axial MRI scan shows disease progression after 3 months from the re-operation (A); after only two cycles 
of temozolomide given with an intensified schedule, with the administration of daily 50 mg/m2 body surface, the lesion enhancement 
slowed down (B), and a third surgical approach was then reconsidered and performed, resulting in total removal of the lesion (C).
A B
C D
A B C
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Figure 4: Axial (A), sagittal (B), 
and coronal (C) T1 weighted post-
contrast MRI shows the extracranial 
invasion of the nasal fossa by the 
lesion. The tumor extends for 6 cm 
on the craniocaudal axis, and causes 
lateral drift of left optic bulb. The 
involvement of left bulb appears 
evident on the straight sight (D).
Figure 5: Intraoperative images shows the endophytic intracranial component of the lesion (A) and cranial anterior fossa reconstruction 
(B,C).
constitute a barrier against glioma cell invasion (11). However, 
our case is an exception. According to Brandes et al. (3), 
dura mater invasion of the GBM was very rarely described 
in the literature and only eight cases have been previously 
reported. Dura mater invasion could be attributed to a slow 
and progressive herniation of the tumor due to an increase of 
intracranial pressure, or a direct invasion of herniated normal 
cerebral tissue. Kawano et al. (7) proposed three routes for 
extradural extension of gliomas: 1. Perivascular or dural slit 
growth; 2. Through cranial or spinal nerves; 3. Direct destruction 
of the dura mater. Pompili et al. (14) described two cases of 
dural spread of gliomas, a GBM and an oligodendroglioma, in 
1993. The first case showed severe intracranial hypertension, 
perforation of the dura mater and the bone defect of the 
cranial base. In the second case, surgery probably facilitated 
the extraneural invasion of the tumor. 
A B
C D
A B C
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The individualized metronomic chemotherapy schedule de-
serves special considerations. This peculiar second line che-
motherapy was only used by Perry and coworkers (13, 12). 
This gave rise to a new perspective. The treatment was well 
tolerated, and the good response allowed further surgical ap-
proach. It may be called “neo-adjuvant chemotherapy”.
We are not able to ensure the role of this chemotherapy on 
the transdural spread of the GBM. Therefore further clinical 
observations are needed. In the future, atypical extracranial 
tumor spread may be more common because of longer 
survival of the patients with GBM due to multidisciplinary 
approach.  
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